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The adenoma–carcinoma sequence of colorectal tumorigenesis
requires accumulation of genetic alterations. Inactivation of the
adenomatous polyposis coli (APC) suppressor gene is the first
event in this sequence, which results in colorectal adenoma forma-
tion (Vogelstein et al, 1988). Recently, it has been reported that
APC mutations are associated with an accumulation of intracel-
lular beta-catenin protein, which leads to loss of control of normal
beta-catenin signalling (Munemitsu et al, 1995). Thus, beta-
catenin may promote colorectal adenoma formation resulting from
the APC mutation. The beta-catenin protein is involved in two
major functions: cell adhesion and mediation of the Wingless/Wnt
signal transduction pathway (Behrens et al, 1996; Barth et al,
1997). Signal transduction of beta-catenin involves post-transla-
tional stabilization and its passage into the nucleus, where it inter-
acts with transcription factors of the T-cell factor or lymphoid
enhancer factor (LEF) family to activate target genes regulating
cell proliferation and apoptosis (Korinek et al, 1997; Morin et al,
1997). Therefore, the specific localization of beta-catenin may
influence its oncogenic activity. Beta-catenin has been reported in
the nuclei and cytoplasm of adenomas and cancers from patients
with familial adenomatous polyposis (FAP) but not in sporadic
cancers (Inomata et al, 1996). Another study showed nuclear
localization with increased expression in most sporadic adenomas
(Valizadeh et al, 1997). To determine if intracellular localization of
beta-catenin might be involved in carcinogenesis, we investigated
beta-catenin localization in sporadic colorectal adenomas and
cancers and in patients with FAP.
MATERIALS AND METHODS
Specimen preparation
Lesions (n = 85) were resected endoscopically (n = 53) or surgi-
cally (n = 22) from 75 patients with sporadic colorectal adenomas
and cancers. Tubular adenomas (n = 29), intramucosal cancers (n =
12) and invasive cancers (n = 44) were evaluated. We also studied
tubular adenomas (n = 63), intramucosal cancers (n = 8) and inva-
sive cancers (n = 11) obtained surgically from 12 patients with
FAP. Six of the 12 FAP patients had adenomatous polyposis
without cancer. The 75 cancers were well- (n = 62), moderately-
(n = 11) and poorly-differentiated (n = 2) adenocarcinomas.
Specimens were fixed in 10% formaline and embedded in paraffin.
Serial sections were prepared for haematoxylin and eosin (H&E)
staining and immunostaining.
Immunohistochemisty
The streptavidin-biotin immunoperoxidase method was employed
for immunostaining of beta-catenin protein. Deparaffinized and
rehydrated sections were heated in a microwave oven in 
0.01 mol l–1 sodium citrate buffer (pH 6.5) for seven 3-min cycles.
Endogenous peroxidase activity was inhibited by incubation with
0.3% hydrogen peroxidase in methanol for 20 min. After blocking
any nonspecific reactions with 10% normal rabbit serum, the
sections were incubated with anti-beta-catenin antibody (1:250,
Transduction Labs, Lexington, KY, USA) for 1 h. Sections were
then incubated with biotinylated rabbit anti-mouse immunoglob-
ulin for 30 min followed by exposure to streptavidin–peroxidase
complex (Histofine SAB-PO kit, Nichirei, Tokyo, Japan) for 
30 min. Colour was then developed with diaminobenzidine solu-
tion. Sections were then lightly counterstained with haematoxylin
and mounted.
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Nuclear staining of positive cells was defined as intense brown
colour in the nucleus. The pattern of nuclear immunostaining was
classed as follows (Figure 1): negative or scattered group, no or
very few scattered positive cells without any clusters; focal group,
positive cells clustered in focal areas; diffuse, over-expressed
group, positive cells distributed diffusely, homogeneously or
heterogeneously.
For evaluation of immunostaining intensity in the cytoplasm,
microscopic images of immunostained sections were measured for
optical density using an image analysis system (SP-500, Olympus,
Tokyo, Japan). In each section, the areas selected were equivalent
to a 100 ´ total magnification lens field. Cytoplasmic intensity of
tumours (T) was analysed by randomly processing 100 tumour
cells per section at a magnification of 400 ´. As an internal control
for each section, normal cytoplasmic intensity (N) was measured in
100 normal mucosa cells near the mucosal surface; immuno-
reactivity of mucosal cells increases gradually from the base of the
crypts to the luminal surface (Inomata et al, 1996). We defined the
cytoplasmic intensity index as follows: (T2N)/mean N of each
group.
Staining intensity of the cell membrane was compared with
normal mucosa cells as an internal positive control; these were
divided into two groups. Tumour cells found to be homogeneously
positive were described as a preserved type, while cases with weak
staining were described as a reduced type.
We correlated subcellular immunoreactivity with histopatho-
logical findings, size of adenoma and invasion of cancer. The
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Figure 1 Three patterns of nuclear immunostaining of beta-catenin. (A) Negative/scattered group, few (or no) nuclear-positive cells scattered without clusters;
bar = 100 mm. (B) Focal group, nuclear-positive cells clustered in focal areas; bar = 100 mm. (C) Diffuse, over-expressed group, nuclear-positive cells distributed
diffusely, homogeneously or heterogeneously; bar = 50 mm
B
Ccytoplasmic intensity of the adenoma or cancer was compared to
normal mucosa using a paired t-test. The cytoplasmic intensity
index was compared using the nonparametric Mann–Whitney U-test
and the Kruskal–Wallis test. The association of nuclear expression
with cell membrane expression was examined by the c2 test.
Probability values smaller than 0.05 were considered statistically
significant.
RESULTS
Nuclear expression of beta-catenin
Nuclear immunoreactivity and the histopathology of colorectal
tumours are presented in Table 1. Diffuse positivity was not
detected in any adenomas from sporadic or FAP (Figure 2) cases.
There was no correlation between nuclear expression and histo-
logical differentiation of cancers. The nuclear positivity of 30
tumours in which cancerous and adenomatous areas were co-
existing is shown in Table 2. Nine cancers with simultaneous
adenomas showed diffuse immunostaining in cancer areas.
However, eight of the nine tumours did not show diffuse nuclear
staining in adenoma components (Figure 3).
Cytoplasmic expression of beta-catenin
Cytoplasmic staining intensity was significantly (P < 0.001) higher
in adenomas (112.2 ± 15.7, mean ± s.d.) and cancers (116.2 ± 18.8)
than in normal mucosa (96.7 ± 12.3), in both sporadic and FAP
cases. The cytoplasmic staining intensity index and histopathology
are presented in Figure 4. The cytoplasmic intensity index of
invasive cancers was significantly higher than that of adenomas in
both sporadic and FAP cases. There was no correlation between
cytoplasmic intensity index and nuclear positivity in either sporadic
or FAP cancers.
Cell membrane expression of beta-catenin
All adenomas from both sporadic and FAP cases showed the
preserved type of cell membrane immunostaining. The reduced
type was significantly (P < 0.02) associated with nuclear expres-
sion in cancers from both sporadic and FAP cases (Table 3). There
was no correlation between cell membrane immunostaining
pattern and cytoplasmic intensity index.
DISCUSSION
In this study, nuclear over-expression of beta-catenin was observed
in 35% (7/20) of intramucosal cancers and 42% (23/55) of 
invasive cancers but was not observed in adenomas from either
sporadic or FAP cases. The frequency of invasive cancers with
nuclear over-expression was higher than the 20% (32/154) value
of a previous report (Günther et al, 1998). We observed that most
cancers which were accompanied by adenomas showed nuclear
over-expression of beta-catenin in the cancer area, but this was not
seen in the adenoma component. Although we did not examine
APC mutation, inherited mutations of APC cause FAP, and
acquired APC mutations are present in approximately 80% of
sporadic colorectal adenomas and cancers (Miyoshi et al, 1992;
Jen et al, 1994). Thus, our findings suggest that nuclear transloca-
tion of beta-catenin is involved in the initiation of intramucosal
cancers rather than adenomas, independent of APC mutations. The
discrepancy with a previous study (Valizadeh et al, 1997) which
showed intense nuclear staining in adenomas may be explained by
different evaluations of immunostaining. Valizadeh et al (1997)
did not examine the frequency or distribution of nuclear-positive
cells. We distinguished the over-expressed staining pattern with
positive cells distributed diffusely and frequently from the pattern
of a few scattered positive cells or clustered positive cells in focal
areas. We consider the over-expressed pattern significant for
tumour formation. Another possible explanation for this discrep-
ancy is different histological criteria for intramucosal cancers
versus adenomas with severe to moderate dysplasia (Schlemper 
et al, 1998). Our results do not agree with the findings of Inomata
et al (1996), who found that beta-catenin was localized predomi-
nantly to the nucleus of adenomas in FAP patients. Although they
used a different fixation method, this discrepancy cannot be
explained by specimen fixation in light of our results in cancers
accompanied by adenomas. Inomata et al (1996) did not describe
the number or size of the adenomas showing nuclear accumula-
tion. We did not find over-expressed staining in any lesions of 43
FAP adenomas which were smaller than 5 mm (Figure 2). We
suggest that nuclear accumulation may not be observed in early-
stage adenomas in FAP patients.
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Table 1 Relationship between nuclear expression of beta-catenin and the
histopathology of colorectal adenomas and cancers
Histopathology Negative/scattered Focal Diffuse
Sporadic adenoma
< 5 mm 13 (100)a 0 (0) 0 (0)
³ 5 mm 14 (88) 2 (13) 0 (0)
Sporadic cancer
Intramucosal 5 (42) 3 (25) 4 (33)
Invasive 24 (55) 3 (7) 17 (39)
FAP adenoma
< 5 mm 43 (100) 0 (0) 0 (0)
³ 5 mm 20 (100) 0 (0) 0 (0)
FAP cancer
Intramucosal 1 (13) 4 (50) 3 (38)
Invasive 3 (27) 2 (18) 6 (55)
aNumbers in parentheses are percentages. Negative/scattered, no or few
scattered positive cells; Focal, positive cells clustered in focal areas; Diffuse,
positive cells distributed diffusely. FAP, familial adenomatous polyposis.
Figure 2 Immunohistochemical staining of beta-catenin in a tubular
adenoma (1 mm) from a patient with familial adenomatous polyposis. Cell
membrane immunostaining is preserved without expression in the nucleus;
bar = 100 mmTo investigate the cause of nuclear translocation of beta-catenin,
we performed polymerase chain reaction (PCR)-single-strand
conformational polymorphism (SSCP) and DNA sequence
analysis for a mutation in exon 3 of the beta-catenin gene
(CTNNB1), using 18 specimens of cancers with nuclear over-
expression. It has been reported that mutations of CTNNB1 can
increase free cytoplasmic beta-catenin (Morin et al, 1997). In only
one of the 18 specimens, however, was a beta-catenin gene muta-
tion found (serine site, data not shown). This result is compatible
with previous reports that mutations in CTNNB1 are uncommon
in colorectal cancers (Kitaeva et al, 1997; Günther et al, 1998;
Iwao et al, 1998; Müller et al, 1998; Samowitz et al, 1999).
Recently, in contrast to the Wnt signal transduction pathway, 
activated integrin-linked kinase (ILK) has been shown to induce
translocation of beta-catenin from the plasma membrane to 
the nucleus, as well as induce the formation of the LEF-1/beta-
catenin complex without an increase in the free pool of cytosolic
beta-catenin (Novak et al, 1998). This evidence agrees with our
finding that nuclear positivity is significantly associated with the
reduced type of cell membrane staining in cancers. Further investi-
gations are needed to reveal the mechanisms underlying nuclear
translocation of beta-catenin.
Cytoplasmic staining intensity was significantly higher in
adenomas than in normal mucosa, irrespective of adenoma size.
Although cytoplasmic beta-catenin was frequently expressed at
high levels in invasive cancers, it was not correlated with nuclear
expression of beta-catenin. Stabilized beta-catenin should pass
into the nucleus to interact with transcription factors and activate
target genes (Korinek et al 1997; Morin et al, 1997). Therefore, it
is likely that cytoplasmic accumulation of beta-catenin starts at the
adenoma stage, but it is unknown whether cytoplasmic accumula-
tion is a cause or a result of the progression from adenoma to
cancer.
Inactivation of APC has been proposed as an initial step in
adenoma formation. Our findings in adenomas of FAP patients
suggest that APC inactivation is not sufficient to promote beta-
catenin nuclear accumulation. It has been reported that the APC
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Table 2 Nuclear expression of beta-catenin in colorectal cancers
accompanied by adenomas
Adenoma area
Cancer area Negative/scattered Focal Diffuse
Negative/scattered 13 (100)a 0 (0) 0 (0)
Focal 4 (50) 4 (50) 0 (0)
Diffuse 7 (78) 1 (11) 1 (11)
aNumbers in parentheses are percentages. Negative/scattered, no or few
scattered positive cells; Focal, positive cells clustered in focal areas; Diffuse,
positive cells distributed diffusely.
A
C
Figure 3 Immunohistochemical staining of beta-catenin in a sporadic cancer
accompanied by an adenoma (15 mm). There is diffuse nuclear staining in the
cancer (C), but few positive cells in the adenoma (A); bar = 50 mm
Table 3 Relationship between cell membrane and nuclear expression of
beta-catenin in colorectal cancers
Nuclear expression
Cell membrane expression Negative/scattered Focal Diffuse
Preserved 27 (61)a 6 (14) 11 (25)
Reduced 6 (19) 6 (19) 19 (61)
aNumbers in parentheses are percentages. Negative/scattered, no or few
scattered positive cells; Focal, positive cells clustered in focal areas; Diffuse,
positive cells distributed diffusely. Cell membrane expression was
significantly associated with nuclear expression (P < 0.02 by c2 test).
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Figure 4 The relationship between cytoplasmic intensity index of beta-
catenin and the histopathology of colorectal adenomas and cancers from
patients with sporadic (A) and familial adenomatous polyposis (B). Columns
and bars represent the mean and standard deviation. For statistical analysis,
the Mann–Whitney and Kruskal–Wallis tests were usedgene regulates the cytoskeleton and promotes cell migration
(Näthke et al, 1996). Loss of these APC functions might be
involved in adenoma formation. P53 mutations are known to occur
at an early stage of carcinoma development (Vogelstein et al,
1988), similar to nuclear localization of beta-catenin. However, we
did not observe any correlation with p53 expression (data not
shown).
In summary, we investigated the status of beta-catenin in the
development of colorectal tumours. We confirmed that localiza-
tion of beta-catenin, especially translocation to the nucleus, may
be associated with progression through the adenoma–carcinoma
sequence.
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